Key Points We used molecular dynamics, saturation mutagenesis, and enzymologic screening to develop a glutaminase-free mutant (Q59L) l-ASP. We then used Q59L to show that glutaminase activity is not required for l-ASP activity against ASNS-negative cancer cells.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: